Jorge S Haro-Cruz, Laura M Rodríguez-Barrios, Ana C Díaz-Degollado, Guillermo Álvarez-Sánchez, Marisol Guitián-González, Claudio D Rojas-Gutiérrez, Erick Zuñiga-Garza, Israel Salgado-Adame, Ruddy F Canaan-Figueroa, Allan F Delcid-Morazán, Sara I Rodríguez-Barrios, Daniel Chacón-Galvis
{"title":"Extranodal Rosai-Dorfman disease in the breast: a literature review from 1969 to 2023.","authors":"Jorge S Haro-Cruz, Laura M Rodríguez-Barrios, Ana C Díaz-Degollado, Guillermo Álvarez-Sánchez, Marisol Guitián-González, Claudio D Rojas-Gutiérrez, Erick Zuñiga-Garza, Israel Salgado-Adame, Ruddy F Canaan-Figueroa, Allan F Delcid-Morazán, Sara I Rodríguez-Barrios, Daniel Chacón-Galvis","doi":"10.24875/CIRU.24000184","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Reviewing available literature regarding extranodal Rosai-Dorfman disease in the breast to explore the clinical characteristics of this disease, the described therapeutic options, and their outcomes.</p><p><strong>Method: </strong>In January 2024, the PubMed, SpringerOpen, and Scopus databases were searched with the keywords \"Rosai,\" \"Dorfman,\" and \"Breast.\" Forty-two studies were included in the final analysis, obtaining a total of 70 reported cases of extranodal Rosai-Dorfman disease affecting the breast. Patient characteristics, mammogram descriptions, therapeutic management, and outcomes were reviewed for statistical analysis.</p><p><strong>Results: </strong>The main population consisted of females in their sixth decade of life (93%), presenting with a firm, non-tender nodule (65.7%), generally localized to one breast (72%). About 18.6% of patients had nodal or extranodal disease in other areas. Excisional biopsy was the main treatment strategy (63%) and surgical excision showed a lesser association with recurrence than incisional biopsy (p = 0.049). Most instances of disease recurrence or progression were diagnosed within the first 2 years.</p><p><strong>Conclusions: </strong>This study revealed that surgical excision showed less association with disease recurrence or progression than expectant management. Follow-up can be conducted with a mammogram and physical examination since recurrence tends to occur locally within 2 years.</p>","PeriodicalId":93936,"journal":{"name":"Cirugia y cirujanos","volume":"92 6","pages":"741-750"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cirugia y cirujanos","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24875/CIRU.24000184","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Reviewing available literature regarding extranodal Rosai-Dorfman disease in the breast to explore the clinical characteristics of this disease, the described therapeutic options, and their outcomes.
Method: In January 2024, the PubMed, SpringerOpen, and Scopus databases were searched with the keywords "Rosai," "Dorfman," and "Breast." Forty-two studies were included in the final analysis, obtaining a total of 70 reported cases of extranodal Rosai-Dorfman disease affecting the breast. Patient characteristics, mammogram descriptions, therapeutic management, and outcomes were reviewed for statistical analysis.
Results: The main population consisted of females in their sixth decade of life (93%), presenting with a firm, non-tender nodule (65.7%), generally localized to one breast (72%). About 18.6% of patients had nodal or extranodal disease in other areas. Excisional biopsy was the main treatment strategy (63%) and surgical excision showed a lesser association with recurrence than incisional biopsy (p = 0.049). Most instances of disease recurrence or progression were diagnosed within the first 2 years.
Conclusions: This study revealed that surgical excision showed less association with disease recurrence or progression than expectant management. Follow-up can be conducted with a mammogram and physical examination since recurrence tends to occur locally within 2 years.